Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia (Q34052075)

30 July 2017

title

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia (English)

1 reference

30 July 2017

1 reference

1 reference

lymphoblastic leukemia

1 reference

35

Peter Hillmen

0 references

Jacqueline Barrientos

Jacqueline C Barrientos

4

0 references

Paul M Barr

Paul M Barr

12

0 references

Julio Delgado

Julio Delgado

20

0 references

Constantine S. Tam

Constantine S Tam

8

0 references

Susan O'Brien

3

Susan O'Brien

1 reference

30 July 2017

27

Claire Dearden

1 reference

30 July 2017

1

John C Byrd

1 reference

30 July 2017

19

Tadeusz Robak

1 reference

30 July 2017

5

Neil E Kay

1 reference

30 July 2017

7

Steven Coutre

1 reference

30 July 2017

30

Alvina D Chu

1 reference

30 July 2017

31

Maria Fardis

1 reference

30 July 2017

32

Jesse McGreivy

1 reference

30 July 2017

33

Fong Clow

1 reference

30 July 2017

34

Danelle F James

1 reference

30 July 2017

29

Jeffrey J Jones

1 reference

30 July 2017

21

Stephen J Schuster

1 reference

30 July 2017

9

Stephen P Mulligan

1 reference

30 July 2017

10

Ulrich Jaeger

1 reference

30 July 2017

15

Florence Cymbalista

1 reference

Federico Caligaris-Cappio

30 July 2017

18

Federico Caligaris-Cappio

1 reference

30 July 2017

22

Marco Montillo

1 reference

30 July 2017

Jennifer R Brown

2

1 reference

30 July 2017

Nishitha M Reddy

6

1 reference

30 July 2017

Steve Devereux

11

1 reference

30 July 2017

Richard R Furman

13

1 reference

30 July 2017

Thomas J Kipps

14

1 reference

30 July 2017

Christopher Pocock

16

1 reference

30 July 2017

Patrick Thornton

17

1 reference

30 July 2017

Anna Schuh

23

1 reference

30 July 2017

Sven de Vos

24

1 reference

30 July 2017

Devinder Gill

25

1 reference

30 July 2017

Adrian Bloor

26

1 reference

30 July 2017

Carol Moreno

28

1 reference

30 July 2017

RESONATE Investigators

36

1 reference

30 July 2017

language of work or name

English

0 references

publication date

31 May 2014

1 reference

The New England Journal of Medicine

30 July 2017

published in

1 reference

30 July 2017

volume

371

1 reference

30 July 2017

issue

3

1 reference

30 July 2017

page(s)

213-223

1 reference

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy

30 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134521

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134521

Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134521

Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134521

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134521

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134521

Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134521

Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134521

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134521

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134521

U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134521

NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134521

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134521

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134521

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134521

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134521

Toxicity and response criteria of the Eastern Cooperative Oncology Group

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134521

A Multiple Testing Procedure for Clinical Trials

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134521

Ibrutinib in relapsed chronic lymphocytic leukemia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134521

Non-Hodgkin's lymphomas, version 1.2013.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134521

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4134521

Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

28 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24881631

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Ibrutinib in relapsed chronic lymphocytic leukemia

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24881631

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1056/NEJMOA1400376

1 reference

30 July 2017

1 reference

30 July 2017

1 reference